Joseph Fallon, MD
Endocrinology, Diabetes & Metabolism · Stratford, NJNPI 1760429369
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $83,136 of the $106,372 with a category attached, or 78.2%. 30 manufacturers reported payments, led by Novo Nordisk at 56.3% of the total. Reporting peaked in 2021 at $27,536 and has fallen 98.0% since, to $549 in 2025. Among endocrinology, diabetes & metabolism clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 326 payments — averaging $326.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$60K
- Amarin Pharma, Inc.$14K
- Mannkind Corporation$8K
- Esperion Therapeutics, Inc.$7K
- Johnson & Johnson$5K
- Bayer$5K
- plus $8K from 24 others
What the payments were for
- Consulting fees$5,2405%
- Speaking & faculty fees$83,13678%
- Travel & lodging$8,8598%
- Food & beverage$8,6758%
- Education$3430%
- Gifts$1190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 69 | $59,906 |
| Amarin Pharma, Inc. | 24 | $13,714 |
| Mannkind Corporation | 50 | $7,619 |
| Esperion Therapeutics, Inc. | 15 | $7,395 |
| Johnson & Johnson | 13 | $5,345 |
| Bayer | 53 | $4,859 |
| IBSA Pharma Inc. | 7 | $3,015 |
| Medtronic | 15 | $1,801 |
| Abbott | 21 | $548 |
| Amneal Pharmaceuticals LLC | 20 | $366 |
| Insulet Corporation | 6 | $253 |
| Amgen | 3 | $230 |
| Sanofi-aventis U.S. LLC | 4 | $153 |
| AbbVie | 5 | $150 |
| GRT US Holding, Inc. | 1 | $125 |
| Exelixis Inc. | 1 | $118 |
| Merck | 1 | $116 |
| Intuity Medical Inc | 1 | $109 |
| Corcept Therapeutics | 1 | $101 |
| Boehringer Ingelheim | 1 | $101 |
| Lilly USA, LLC | 4 | $100 |
| Valeritas, Inc. | 1 | $98 |
| Nevro Corp. | 2 | $37 |
| Ascendis Pharma Endocrinology Inc | 2 | $33 |
| Radius Health, Inc. | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Amryt Pharma Holdings Ltd | 1 | $15 |
| OPKO Pharmaceuticals, LLC | 1 | $14 |
| AstraZeneca | 1 | $12 |
| Clarus Therapeutics Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Saxenda$44,143
- Wegovy$14,804
- Vascepa$13,246
- NEXLIZET$7,227
- NEXLETOL$7,227
- AFREZZA$7,017
- INVOKANA$5,041
- Tirosint$5,000
- Kerendia$4,113
- MINIMED 780G$1,410
- Tirosint-SOL$500
- VERQUVO$232
- FreeStyle Libre 2$150
- Qutenza$125
- Cabometyx$118
- FREESTYLE LIBRE 3$116
- Pogo Automatic Blood Glucose Monitoring System$109
- EVENITY$108
- TEPEZZA$108
- TZIELD$106
How this compares
$106,372 in reported general payments places this provider in the 95th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
See all endocrinology, diabetes & metabolism providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 571 | $868,704 |
| JardianceEmpagliflozin | 421 | $500,182 |
| TrulicityDulaglutide | 269 | $480,210 |
| FarxigaDapagliflozin Propanediol | 278 | $358,811 |
| MounjaroTirzepatide | 161 | $208,963 |
| RybelsusSemaglutide | 97 | $200,467 |
| VascepaIcosapent Ethyl | 228 | $167,416 |
| SynthroidLevothyroxine Sodium | 1,264 | $146,991 |
| JanuviaSitagliptin Phosphate | 110 | $136,992 |
| InvokanaCanagliflozin | 93 | $121,896 |
| Tresiba Flextouch U-100Insulin Degludec | 130 | $113,252 |
| TradjentaLinagliptin | 90 | $92,159 |
| KerendiaFinerenone | 56 | $65,181 |
| Tresiba Flextouch U-200Insulin Degludec | 41 | $59,525 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 39 | $40,832 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $59,906 | $1,085,521701 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $100 | $703,179482 claims |
| Boehringer IngelheimJardiance, Tradjenta | $101 | $592,340511 claims |
| AstraZenecaFarxiga | $12 | $358,811278 claims |
| MerckJanuvia, Steglatro, Janumet Xr | $116 | $166,312146 claims |
| AbbVieSynthroid | $150 | $146,9911,264 claims |
| Johnson & JohnsonInvokana | $5,345 | $121,89693 claims |
| BayerKerendia | $4,859 | $65,18156 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $366 | $35,3082,118 claims |
| Esperion Therapeutics, Inc.Nexletol | $7,395 | $23,45826 claims |
| AmgenProlia | $230 | $21,73612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
Other endocrinology, diabetes & metabolism in Stratford
- Barry GertzRahway$903K
- Nawras MakhsidaRandolph$882K
- Marc SandbergFlemington$567K
- Joanne WaldstreicherNew Brunswick$441K
- Gregory BaroneCherry Hill$433K
- Navtika DesaiHillsborough$408K
- Taher ModarressiPennington$402K
- Atara SchultzTeaneck$357K
- Anthony CannonTurnersville$296K
- Stanislav GoykhmanLyndhurst$278K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.